Net profit of Jubilant Ingrevia rose 2.63% to Rs 59.00 crore in the quarter ended September 2024 as against Rs 57.49 crore during the previous quarter ended September 2023. Sales rose 1.77% to Rs 1029.00 crore in the quarter ended September 2024 as against Rs 1011.10 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales1029.001011.10 2 OPM %12.0911.64 - PBDT119.82113.78 5 PBT80.2279.87 0 NP59.0057.49 3 Powered by Capital Market - Live

Jubilant Ingrevia has appointed Vijay Srivastava as Chief of Operations & Whole-time Director of the Company subject to the approval of shareholders, effective from 01 November 2024 for a period of 5 years.Powered by Capital Market - Live

Jubilant Ingrevia will hold a meeting of the Board of Directors of the Company on 22 October 2024.Powered by Capital Market - Live

This partnership will focus on the production of an agro intermediate essential for one of the customer's key agro active products. Manufactured Agro Intermediate will be exported from India. The overall consideration will pay based on the revenue of around $300 million plus from supplies of the Agro intermediate to the customer, over a period of next few years after commencement of production. 'A synergistic relationship where JASL leverages its manufacturing prowess coupled with customer's technology knowhow of key Agro intermediates and Agro actives, global distribution network and brand image in the agrarian space', the firm said. Jubilant Ingrevia is a global integrated life science products and innovative solutions provider serving, pharmaceutical, nutrition, agrochemical, consumer and industrial customers with its customised products and solutions that are innovative, cost effective and conforming to premium quality standards. The company is engaged in manufacturing and supply of speciality chemicals, nutrition & health solutions and chemical intermediates through five manufacturing facilities in India. The company reported 15.36% decline in consolidated net profit to Rs 48.74 crore in Q1 FY25 as compared with net profit of Rs 57.59 crore in Q1 FY24. Total revenue from operations stood at Rs 1,024.34 crore in Q1 FY25, down 4.71% from Rs 1,075.02 crore in Q1 FY24. The scrip hit 52-week high at Rs 836.95 in intraday today.Powered by Capital Market - Live

Jubilant Ingrevia has redeemed commercial paper of Rs 100 crore on 20 September 2024 (maturity date). Powered by Capital Market - Live

Morepen Laboratories Ltd, Religare Enterprises Ltd, Mazagon Dock Shipbuilders Ltd and DCW Ltd are among the other gainers in the BSE's 'A' group today, 04 September 2024.Jubilant Ingrevia Ltd soared 7.92% to Rs 727.25 at 11:45 IST. The stock was the biggest gainer in the BSE's 'A' group. On the BSE, 3.06 lakh shares were traded on the counter so far as against the average daily volumes of 77985 shares in the past one month. Morepen Laboratories Ltd surged 7.60% to Rs 88.45. The stock was the second biggest gainer in 'A' group. On the BSE, 16.55 lakh shares were traded on the counter so far as against the average daily volumes of 28.24 lakh shares in the past one month. Religare Enterprises Ltd spiked 5.85% to Rs 283.85. The stock was the third biggest gainer in 'A' group. On the BSE, 89155 shares were traded on the counter so far as against the average daily volumes of 83759 shares in the past one month. Mazagon Dock Shipbuilders Ltd spurt 5.82% to Rs 4715. The stock was the fourth biggest gainer in 'A' group. On the BSE, 4.31 lakh shares were traded on the counter so far as against the average daily volumes of 1.99 lakh shares in the past one month. DCW Ltd rose 5.38% to Rs 88.85. The stock was the fifth biggest gainer in 'A' group. On the BSE, 4.86 lakh shares were traded on the counter so far as against the average daily volumes of 7.45 lakh shares in the past one month. Powered by Capital Market - Live

Jubilant Ingrevia has received credit ratings from India Ratings and Research as under: Proposed commercial paper (Rs 400 crore) - IND A1+ (assigned) Term loan (Rs 300 crore) - IND AA+/ Stable (affirmed) Term loan (Rs 120 crore) - IND AA+/ Stable (assigned) Fund based limit (Rs 700 crore) - IND AA+/Stable/ IND A1+ (affirmed) Non fund based limit (Rs 1,300 crore) - IND A1+ (affirmed) Powered by Capital Market - Live

Jubilant Ingrevia announced that the 5th Annual General Meeting (AGM) of the company will be held on 30 August 2024.Powered by Capital Market - Live

Jubilant Ingrevia has redeemed commercial paper of Rs 100 crore on maturity date of 25 July 2024. Powered by Capital Market - Live